Embecta (NASDAQ:EMBC) Stock Price Down 5% – Here’s What Happened

Embecta Corp. (NASDAQ:EMBC) shares were down 5% during trading on Monday . The company traded as low as $10.10 and last traded at $10.3160. Approximately 123,935 shares changed hands during mid-day trading, a decline of 81% from the average daily volume of 643,474 shares. The stock had previously closed at $10.86.

Wall Street Analysts Forecast Growth

EMBC has been the topic of a number of recent research reports. Wall Street Zen lowered Embecta from a “strong-buy” rating to a “buy” rating in a research note on Saturday. Weiss Ratings reiterated a “hold (c-)” rating on shares of Embecta in a research report on Wednesday, January 21st. Finally, BTIG Research restated a “buy” rating and issued a $25.00 price target on shares of Embecta in a research report on Friday. One analyst has rated the stock with a Buy rating and three have issued a Hold rating to the company’s stock. According to MarketBeat.com, the stock presently has a consensus rating of “Hold” and an average target price of $18.50.

Embecta Trading Down 5.2%

The business’s 50-day simple moving average is $11.76 and its two-hundred day simple moving average is $12.98. The firm has a market cap of $609.97 million, a price-to-earnings ratio of 4.35 and a beta of 1.11.

Embecta (NASDAQ:EMBC) last posted its quarterly earnings data on Thursday, February 5th. The company reported $0.71 EPS for the quarter, beating analysts’ consensus estimates of $0.67 by $0.04. Embecta had a net margin of 12.92% and a negative return on equity of 26.66%. The company had revenue of $261.20 million for the quarter, compared to analyst estimates of $258.07 million. During the same period in the prior year, the firm posted $0.65 EPS. The company’s quarterly revenue was down .3% on a year-over-year basis. Embecta has set its FY 2026 guidance at 2.800-3.00 EPS. On average, analysts forecast that Embecta Corp. will post 2.85 earnings per share for the current fiscal year.

Embecta Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, March 17th. Stockholders of record on Friday, February 27th will be given a dividend of $0.15 per share. This represents a $0.60 dividend on an annualized basis and a dividend yield of 5.8%. The ex-dividend date of this dividend is Friday, February 27th. Embecta’s dividend payout ratio is 25.32%.

Institutional Inflows and Outflows

Institutional investors have recently added to or reduced their stakes in the company. Exchange Traded Concepts LLC boosted its position in shares of Embecta by 519.2% in the third quarter. Exchange Traded Concepts LLC now owns 124,429 shares of the company’s stock valued at $1,756,000 after acquiring an additional 104,334 shares during the period. Teacher Retirement System of Texas lifted its stake in Embecta by 365.7% in the 3rd quarter. Teacher Retirement System of Texas now owns 372,451 shares of the company’s stock worth $5,255,000 after purchasing an additional 292,477 shares in the last quarter. Squarepoint Ops LLC boosted its holdings in Embecta by 103.6% in the 2nd quarter. Squarepoint Ops LLC now owns 403,412 shares of the company’s stock valued at $3,909,000 after purchasing an additional 205,311 shares during the period. American Century Companies Inc. grew its position in shares of Embecta by 36.3% during the 2nd quarter. American Century Companies Inc. now owns 5,195,948 shares of the company’s stock valued at $50,349,000 after purchasing an additional 1,382,537 shares in the last quarter. Finally, Allianz Asset Management GmbH grew its position in shares of Embecta by 68.4% during the 2nd quarter. Allianz Asset Management GmbH now owns 52,044 shares of the company’s stock valued at $504,000 after purchasing an additional 21,144 shares in the last quarter. 93.83% of the stock is owned by institutional investors and hedge funds.

About Embecta

Embecta Corp (NASDAQ: EMBC) is a pure-play diabetes care company that was spun off from Becton, Dickinson and Company on July 1, 2021. Headquartered in Franklin Lakes, New Jersey, Embecta focuses exclusively on the development, manufacturing and commercialization of products that enable insulin delivery and blood glucose monitoring for people with diabetes.

The company’s product portfolio includes insulin infusion sets, durable and patch pumps, pen needles, infusion tubing, blood glucose test strips, lancets and lancing devices.